Immix Biopharma (IMMX) Enterprise Value (2020 - 2026)
Immix Biopharma (IMMX) posted Enterprise Value of -$90.6 million for Q1 2026, up 9.81% sequentially from -$100.4 million in Q4 2025, and down 468.93% YoY from $24.6 million in Q1 2025.
Immix Biopharma (IMMX) Enterprise Value (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Enterprise Value for 7 years, with the latest figure at -$90.6 million in Q1 2026.
- Quarterly Enterprise Value fell 468.93% year-over-year to -$90.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$90.6 million (down 468.93% YoY) and the FY2025 annual result came in at -$100.4 million, down 467.97% from the prior year.
- Enterprise Value climbed to -$90.6 million in Q1 2026 per IMMX's latest filing, from -$100.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$11.5 million in Q1 2023 and troughed at -$100.4 million in Q4 2025.
- A 5-year average of -$26.8 million and a median of -$17.7 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value jumped 51.62% in 2025, then tumbled 468.93% in 2026.
- Over 5 years, Enterprise Value stood at -$13.4 million in 2022, then plunged by 31.81% to -$17.7 million in 2023, then grew by 0.17% to -$17.7 million in 2024, then slumped by 467.97% to -$100.4 million in 2025, then increased by 9.81% to -$90.6 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$90.6 million, -$100.4 million, and -$15.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | -238.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -238.72 Mn |
| Mar 31, 2026 | -90.58 Mn |
| Dec 31, 2025 | -100.43 Mn |
| Sep 30, 2025 | -15.95 Mn |
| Jun 30, 2025 | -11.60 Mn |
| Mar 31, 2025 | -15.92 Mn |
| Dec 31, 2024 | -17.68 Mn |
| Sep 30, 2024 | -19.69 Mn |
| Jun 30, 2024 | -23.98 Mn |
| Mar 31, 2024 | -29.60 Mn |
| Dec 31, 2023 | -17.71 Mn |
| Sep 30, 2023 | -19.71 Mn |
| Jun 30, 2023 | -12.71 Mn |
| Mar 31, 2023 | -11.50 Mn |
| Dec 31, 2022 | -13.44 Mn |
| Sep 30, 2022 | -16.92 Mn |
| Jun 30, 2022 | -18.40 Mn |
| Mar 31, 2022 | -19.06 Mn |
| Dec 31, 2021 | -17.64 Mn |
| Dec 31, 2020 | -391,086.00 |